Host |
Mouse |
Klon |
ZM123 |
Format |
Ready-to-use |
Reaktivität |
- |
Methode |
P |
Positivkontrolle |
Breast carcinoma. |
Verdünnung |
- |
Isotyp |
IgG1 /κ |
Verdünnung |
Recombinant full-length human KRT8 protein |
Lokalisation |
Cytoplasm |
Cytokeratin 8
|
Zeta Corporation |
ZM123 |
7 ml |
Ready-to-use |
CE/IVD |
Z2433MP |
-
|
Host |
Mouse |
Klon |
ZM123 |
Format |
Concentrate |
Reaktivität |
- |
Methode |
P |
Positivkontrolle |
Breast carcinoma. |
Verdünnung |
1:100 - 1:200 |
Isotyp |
IgG1 /κ |
Verdünnung |
Recombinant full-length human KRT8 protein |
Lokalisation |
Cytoplasm |
Cytokeratin 8
|
Zeta Corporation |
ZM123 |
0.5 ml |
Concentrate |
CE/IVD |
Z2433MS |
-
|
Host |
Mouse |
Klon |
ZM123 |
Format |
Concentrate |
Reaktivität |
- |
Methode |
P |
Positivkontrolle |
Breast carcinoma. |
Verdünnung |
1:100 - 1:200 |
Isotyp |
IgG1 /κ |
Verdünnung |
Recombinant full-length human KRT8 protein |
Lokalisation |
Cytoplasm |
Cytokeratin 8
|
Zeta Corporation |
ZM123 |
0.1 ml |
Concentrate |
CE/IVD |
Z2433MT |
-
|
Host |
Rabbit |
Klon |
EP7 + EP30 |
Format |
Ready-to-use |
Methode |
P |
Vorbehandlung |
Citrate |
Positivkontrolle |
Colon cancer |
Verdünnung |
- |
Isotyp |
IgG |
Lokalisation |
Cytoplasm |
Cytokeratin 8 & 18
|
Biocare Medical |
EP7 + EP30 |
6 ml |
Ready-to-use |
CE/IVD |
API3161AA |
-
|
Host |
Mouse |
Klon |
5D3 |
Format |
Concentrate |
Methode |
F, P |
Vorbehandlung |
Pepsin or Trypsin |
Positivkontrolle |
Skin |
Verdünnung |
1:25 - 1:50 |
Isotyp |
Mouse IgG1 |
Lokalisation |
Cytoplasm |
Cytokeratin 8 & 18
|
Diagnostic Biosystems |
5D3 |
1 ml |
Concentrate |
CE/IVD |
MOB189 |
-
|
Host |
Mouse |
Klon |
5D3 |
Format |
Concentrate |
Methode |
F, P |
Vorbehandlung |
Pepsin or Trypsin |
Positivkontrolle |
Skin |
Verdünnung |
1:25 - 1:50 |
Isotyp |
Mouse IgG1 |
Lokalisation |
Cytoplasm |
Cytokeratin 8 & 18
|
Diagnostic Biosystems |
5D3 |
0.1 ml |
Concentrate |
CE/IVD |
MOB189-01 |
-
|
Host |
Mouse |
Klon |
5D3 |
Format |
Concentrate |
Methode |
F, P |
Vorbehandlung |
Pepsin or Trypsin |
Positivkontrolle |
Skin |
Verdünnung |
1:25 - 1:50 |
Isotyp |
Mouse IgG1 |
Lokalisation |
Cytoplasm |
Cytokeratin 8 & 18
|
Diagnostic Biosystems |
5D3 |
0.5 ml |
Concentrate |
CE/IVD |
MOB189-05 |
-
|
Host |
Mouse |
Klon |
IVT-2000 |
Format |
Ready-to-use |
Methode |
P |
Vorbehandlung |
Citrate or Fast Enzyme |
Verdünnung |
- |
Isotyp |
Mouse IgG |
Lokalisation |
Cytoplasm |
Cytokeratin 8 & 18
|
Zytomed Systems GmbH |
IVT-2000 |
6 ml |
Ready-to-use |
RUO |
MSG035 |
-
|
Host |
Mouse |
Klon |
IVT-2000 |
Format |
Concentrate |
Methode |
P |
Vorbehandlung |
Citrate or Fast Enzyme |
Verdünnung |
1:100 - 1:200 |
Isotyp |
Mouse IgG |
Lokalisation |
Cytoplasm |
Cytokeratin 8 & 18
|
Zytomed Systems GmbH |
IVT-2000 |
1 ml |
Concentrate |
RUO |
MSK035 |
-
|
Host |
Mouse |
Klon |
IVT-2000 |
Format |
Concentrate |
Methode |
P |
Vorbehandlung |
Citrate or Fast Enzyme |
Verdünnung |
1:100 - 1:200 |
Isotyp |
Mouse IgG |
Lokalisation |
Cytoplasm |
Cytokeratin 8 & 18
|
Zytomed Systems GmbH |
IVT-2000 |
0.5 ml |
Concentrate |
RUO |
MSK035-05 |
-
|
Host |
Mouse |
Klon |
5D3 |
Format |
Ready-to-use |
Methode |
F, P |
Vorbehandlung |
Pepsin or Trypsin |
Positivkontrolle |
Skin |
Verdünnung |
- |
Isotyp |
Mouse IgG1 |
Lokalisation |
Cytoplasm |
Cytokeratin 8 & 18
|
Diagnostic Biosystems |
5D3 |
6 ml |
Ready-to-use |
CE/IVD |
PDM070 |
-
|
Host |
Mouse |
Klon |
B22.1/B23.1 |
Format |
Concentrate |
Reaktivität |
- |
Methode |
P |
Positivkontrolle |
Skin, breast carcinoma. |
Verdünnung |
1:100 - 1:200 |
Isotyp |
IgG1 /κ + IgG1 /κ |
Verdünnung |
Cytokeratins purified from breast cancer MCF-7 cells |
Lokalisation |
Cytoplasm |
Cytokeratin 8/18
|
Zeta Corporation |
B22.1/B23.1 |
1ml |
Concentrate |
CE/IVD |
Z2252ML |
-
|
Host |
Mouse |
Klon |
B22.1/B23.1 |
Format |
Ready-to-use |
Reaktivität |
- |
Methode |
P |
Positivkontrolle |
Skin, breast carcinoma. |
Verdünnung |
- |
Isotyp |
IgG1 /κ + IgG1 /κ |
Verdünnung |
Cytokeratins purified from breast cancer MCF-7 cells |
Lokalisation |
Cytoplasm |
Cytokeratin 8/18
|
Zeta Corporation |
B22.1/B23.1 |
7 ml |
Ready-to-use |
CE/IVD |
Z2252MP |
-
|
Host |
Mouse |
Klon |
B22.1/B23.1 |
Format |
Concentrate |
Reaktivität |
- |
Methode |
P |
Positivkontrolle |
Skin, breast carcinoma. |
Verdünnung |
1:100 - 1:200 |
Isotyp |
IgG1 /κ + IgG1 /κ |
Verdünnung |
Cytokeratins purified from breast cancer MCF-7 cells |
Lokalisation |
Cytoplasm |
Cytokeratin 8/18
|
Zeta Corporation |
B22.1/B23.1 |
0.5 ml |
Concentrate |
CE/IVD |
Z2252MS |
-
|
Host |
Mouse |
Klon |
B22.1/B23.1 |
Format |
Concentrate |
Reaktivität |
- |
Methode |
P |
Positivkontrolle |
Skin, breast carcinoma. |
Verdünnung |
1:100 - 1:200 |
Isotyp |
IgG1 /κ + IgG1 /κ |
Verdünnung |
Cytokeratins purified from breast cancer MCF-7 cells |
Lokalisation |
Cytoplasm |
Cytokeratin 8/18
|
Zeta Corporation |
B22.1/B23.1 |
0.1 ml |
Concentrate |
CE/IVD |
Z2252MT |
-
|
Host |
Mouse |
Klon |
ZM125 |
Format |
Concentrate |
Reaktivität |
- |
Methode |
P |
Positivkontrolle |
Skin, breast carcinoma. |
Verdünnung |
1:100 - 1:200 |
Isotyp |
IgG1 /κ |
Verdünnung |
Cytoskeleton preparation from HeLa cells |
Lokalisation |
Cytoplasm |
Cytokeratin 8/18
|
Zeta Corporation |
ZM125 |
1.0 ml |
Concentrate |
CE/IVD |
Z2435ML |
-
|
Host |
Mouse |
Klon |
ZM125 |
Format |
Ready-to-use |
Reaktivität |
- |
Methode |
P |
Positivkontrolle |
Skin, breast carcinoma. |
Verdünnung |
- |
Isotyp |
IgG1 /κ |
Verdünnung |
Cytoskeleton preparation from HeLa cells |
Lokalisation |
Cytoplasm |
Cytokeratin 8/18
|
Zeta Corporation |
ZM125 |
7 ml |
Ready-to-use |
CE/IVD |
Z2435MP |
-
|
Host |
Mouse |
Klon |
ZM125 |
Format |
Concentrate |
Reaktivität |
- |
Methode |
P |
Positivkontrolle |
Skin, breast carcinoma. |
Verdünnung |
1:100 - 1:200 |
Isotyp |
IgG1 /κ |
Verdünnung |
Cytoskeleton preparation from HeLa cells |
Lokalisation |
Cytoplasm |
Cytokeratin 8/18
|
Zeta Corporation |
ZM125 |
0.5 ml |
Concentrate |
CE/IVD |
Z2435MS |
-
|
Host |
Mouse |
Klon |
ZM125 |
Format |
Concentrate |
Reaktivität |
- |
Methode |
P |
Positivkontrolle |
Skin, breast carcinoma. |
Verdünnung |
1:100 - 1:200 |
Isotyp |
IgG1 /κ |
Verdünnung |
Cytoskeleton preparation from HeLa cells |
Lokalisation |
Cytoplasm |
Cytokeratin 8/18
|
Zeta Corporation |
ZM125 |
0.1 ml |
Concentrate |
CE/IVD |
Z2435MT |
-
|
Host |
Mouse |
Klon |
Ks-1A3 |
Format |
Concentrate |
Methode |
F, P |
Vorbehandlung |
Citrate |
Positivkontrolle |
Skin |
Verdünnung |
1:25 - 1:100 |
Isotyp |
Mouse IgG |
Lokalisation |
Cytoplasm |
Cytokeratin 13
|
Diagnostic Biosystems |
Ks-1A3 |
1 ml |
Concentrate |
CE/IVD |
MOB443 |
-
|
Host |
Mouse |
Klon |
Ks-1A3 |
Format |
Concentrate |
Methode |
F, P |
Vorbehandlung |
Citrate |
Positivkontrolle |
Skin |
Verdünnung |
1:25 - 1:100 |
Isotyp |
Mouse IgG |
Lokalisation |
Cytoplasm |
Cytokeratin 13
|
Diagnostic Biosystems |
Ks-1A3 |
0.1 ml |
Concentrate |
CE/IVD |
MOB443-01 |
-
|
Host |
Mouse |
Klon |
Ks-1A3 |
Format |
Concentrate |
Methode |
F, P |
Vorbehandlung |
Citrate |
Positivkontrolle |
Skin |
Verdünnung |
1:25 - 1:100 |
Isotyp |
Mouse IgG |
Lokalisation |
Cytoplasm |
Cytokeratin 13
|
Diagnostic Biosystems |
Ks-1A3 |
0.5 ml |
Concentrate |
CE/IVD |
MOB443-05 |
-
|
Host |
Mouse |
Klon |
LL002 |
Format |
Purified |
Methode |
F, P |
Vorbehandlung |
Citrate |
Positivkontrolle |
Skin |
Isotyp |
Mouse IgG3 |
Verdünnung |
Last 15 C-terminal residues of human Cytokeratin 14 conjugated to Thyroglobulin |
Cytokeratin 14
|
Zytomed Systems GmbH |
LL002 |
20 µg |
Purified |
RUO |
601-2167 |
-
|
Host |
Mouse |
Klon |
LL002 |
Format |
Concentrate |
Methode |
F, P |
Vorbehandlung |
Citrate |
Positivkontrolle |
Skin |
Verdünnung |
1:25 - 1:75 |
Isotyp |
Mouse IgG3 |
Lokalisation |
Cytoplasm |
Cytokeratin 14
|
Diagnostic Biosystems |
LL002 |
1 ml |
Concentrate |
CE/IVD |
MOB186 |
-
|
Host |
Mouse |
Klon |
LL002 |
Format |
Concentrate |
Methode |
F, P |
Vorbehandlung |
Citrate |
Positivkontrolle |
Skin |
Verdünnung |
1:25 - 1:75 |
Isotyp |
Mouse IgG3 |
Lokalisation |
Cytoplasm |
Cytokeratin 14
|
Diagnostic Biosystems |
LL002 |
0.1 ml |
Concentrate |
CE/IVD |
MOB186-01 |
-
|
Host |
Mouse |
Klon |
LL002 |
Format |
Concentrate |
Methode |
F, P |
Vorbehandlung |
Citrate |
Positivkontrolle |
Skin |
Verdünnung |
1:25 - 1:75 |
Isotyp |
Mouse IgG3 |
Lokalisation |
Cytoplasm |
Cytokeratin 14
|
Diagnostic Biosystems |
LL002 |
0.5 ml |
Concentrate |
CE/IVD |
MOB186-05 |
-
|
Host |
Mouse |
Klon |
LL002 |
Format |
Ready-to-use |
Methode |
F, P |
Vorbehandlung |
Citrate |
Positivkontrolle |
Skin |
Verdünnung |
- |
Isotyp |
Mouse IgG3 |
Lokalisation |
Cytoplasm |
Cytokeratin 14
|
Diagnostic Biosystems |
LL002 |
6 ml |
Ready-to-use |
CE/IVD |
PDM138 |
-
|
Host |
Mouse |
Klon |
LL002 |
Format |
Concentrate |
Reaktivität |
- |
Methode |
P |
Positivkontrolle |
Skin, tonsil or squamous cell carcinoma. |
Verdünnung |
1:100 - 1:300 |
Isotyp |
IgG3 /κ |
Verdünnung |
A synthetic peptide of 15 amino acid residues from the C-terminus of human keratin 14 |
Lokalisation |
Cytoplasm |
Cytokeratin 14
|
Zeta Corporation |
LL002 |
1 ml |
Concentrate |
CE/IVD |
Z2042ML |
-
|
Host |
Mouse |
Klon |
LL002 |
Format |
Ready-to-use |
Reaktivität |
- |
Methode |
P |
Positivkontrolle |
Skin, tonsil or squamous cell carcinoma. |
Verdünnung |
- |
Isotyp |
IgG3 /κ |
Verdünnung |
A synthetic peptide of 15 amino acid residues from the C-terminus of human keratin 14 |
Lokalisation |
Cytoplasm |
Cytokeratin 14
|
Zeta Corporation |
LL002 |
7 ml |
Ready-to-use |
CE/IVD |
Z2042MP |
-
|
Host |
Mouse |
Klon |
LL002 |
Format |
Concentrate |
Reaktivität |
- |
Methode |
P |
Positivkontrolle |
Skin, tonsil or squamous cell carcinoma. |
Verdünnung |
1:100 - 1:300 |
Isotyp |
IgG3 /κ |
Verdünnung |
A synthetic peptide of 15 amino acid residues from the C-terminus of human keratin 14 |
Lokalisation |
Cytoplasm |
Cytokeratin 14
|
Zeta Corporation |
LL002 |
0.5 ml |
Concentrate |
CE/IVD |
Z2042MS |
-
|
Host |
Mouse |
Klon |
LL002 |
Format |
Concentrate |
Reaktivität |
- |
Methode |
P |
Positivkontrolle |
Skin, tonsil or squamous cell carcinoma. |
Verdünnung |
1:100 - 1:300 |
Isotyp |
IgG3 /κ |
Verdünnung |
A synthetic peptide of 15 amino acid residues from the C-terminus of human keratin 14 |
Lokalisation |
Cytoplasm |
Cytokeratin 14
|
Zeta Corporation |
LL002 |
0.1 ml |
Concentrate |
CE/IVD |
Z2042MT |
-
|
Host |
Mouse |
Klon |
LHK15 |
Format |
Concentrate |
Methode |
F, P |
Vorbehandlung |
Citrate |
Positivkontrolle |
Skin |
Verdünnung |
1:25 - 1:75 |
Isotyp |
Mouse IgG2a |
Lokalisation |
Cytoplasm |
Cytokeratin 15
|
Diagnostic Biosystems |
LHK15 |
1 ml |
Concentrate |
CE/IVD |
MOB305 |
-
|
Host |
Mouse |
Klon |
LHK15 |
Format |
Concentrate |
Methode |
F, P |
Vorbehandlung |
Citrate |
Positivkontrolle |
Skin |
Verdünnung |
1:25 - 1:75 |
Isotyp |
Mouse IgG2a |
Lokalisation |
Cytoplasm |
Cytokeratin 15
|
Diagnostic Biosystems |
LHK15 |
0.1 ml |
Concentrate |
CE/IVD |
MOB305-01 |
-
|
Host |
Mouse |
Klon |
LHK15 |
Format |
Concentrate |
Methode |
F, P |
Vorbehandlung |
Citrate |
Positivkontrolle |
Skin |
Verdünnung |
1:25 - 1:75 |
Isotyp |
Mouse IgG2a |
Lokalisation |
Cytoplasm |
Cytokeratin 15
|
Diagnostic Biosystems |
LHK15 |
0.5 ml |
Concentrate |
CE/IVD |
MOB305-05 |
-
|
Host |
Mouse |
Klon |
LL025 |
Format |
Concentrate |
Methode |
F, P |
Vorbehandlung |
Citrate |
Positivkontrolle |
Skin |
Verdünnung |
1:25 - 1:75 |
Isotyp |
Mouse IgG1 |
Lokalisation |
Cytoplasm |
Cytokeratin 16
|
Diagnostic Biosystems |
LL025 |
1 ml |
Concentrate |
CE/IVD |
MOB273 |
-
|
Host |
Mouse |
Klon |
LL025 |
Format |
Concentrate |
Methode |
F, P |
Vorbehandlung |
Citrate |
Positivkontrolle |
Skin |
Verdünnung |
1:25 - 1:75 |
Isotyp |
Mouse IgG1 |
Lokalisation |
Cytoplasm |
Cytokeratin 16
|
Diagnostic Biosystems |
LL025 |
0.1 ml |
Concentrate |
CE/IVD |
MOB273-01 |
-
|
Host |
Mouse |
Klon |
LL025 |
Format |
Concentrate |
Methode |
F, P |
Vorbehandlung |
Citrate |
Positivkontrolle |
Skin |
Verdünnung |
1:25 - 1:75 |
Isotyp |
Mouse IgG1 |
Lokalisation |
Cytoplasm |
Cytokeratin 16
|
Diagnostic Biosystems |
LL025 |
0.5 ml |
Concentrate |
CE/IVD |
MOB273-05 |
-
|
Host |
Mouse |
Klon |
E3 |
Format |
Concentrate |
Methode |
F, P |
Vorbehandlung |
Citrate |
Positivkontrolle |
Skin |
Verdünnung |
1:25 - 1:50 |
Isotyp |
Mouse IgG2b |
Lokalisation |
Cytoplasm |
Cytokeratin 17
|
Diagnostic Biosystems |
E3 |
1 ml |
Concentrate |
CE/IVD |
MOB127 |
-
|
Host |
Mouse |
Klon |
E3 |
Format |
Concentrate |
Methode |
F, P |
Vorbehandlung |
Citrate |
Positivkontrolle |
Skin |
Verdünnung |
1:25 - 1:50 |
Isotyp |
Mouse IgG2b |
Lokalisation |
Cytoplasm |
Cytokeratin 17
|
Diagnostic Biosystems |
E3 |
0.1 ml |
Concentrate |
CE/IVD |
MOB127-01 |
-
|
Host |
Mouse |
Klon |
E3 |
Format |
Concentrate |
Methode |
F, P |
Vorbehandlung |
Citrate |
Positivkontrolle |
Skin |
Verdünnung |
1:25 - 1:50 |
Isotyp |
Mouse IgG2b |
Lokalisation |
Cytoplasm |
Cytokeratin 17
|
Diagnostic Biosystems |
E3 |
0.5 ml |
Concentrate |
CE/IVD |
MOB127-05 |
-
|
Host |
Mouse |
Klon |
E3 |
Format |
ready-to-use |
Methode |
F, P |
Vorbehandlung |
Citrate |
Positivkontrolle |
Skin |
Verdünnung |
--- |
Isotyp |
Mouse IgG2b |
Lokalisation |
Cytoplasm |
Cytokeratin 17
|
Diagnostic Biosystems |
E3 |
6 ml |
ready-to-use |
CE/IVD |
PDM206 |
-
|
Host |
Mouse |
Klon |
E3 |
Format |
Concentrate |
Reaktivität |
- |
Methode |
P |
Positivkontrolle |
Squamous cell carcinoma or skin. |
Verdünnung |
1:100 - 1:200 |
Isotyp |
IgG2b /κ |
Verdünnung |
Keratin purified from rat enterocytes |
Lokalisation |
Cytoplasm |
Cytokeratin 17
|
Zeta Corporation |
E3 |
1.0 ml |
Concentrate |
CE/IVD |
Z2254ML |
-
|
Host |
Mouse |
Klon |
E3 |
Format |
Ready-to-use |
Reaktivität |
- |
Methode |
P |
Positivkontrolle |
Squamous cell carcinoma or skin. |
Verdünnung |
- |
Isotyp |
IgG2b /κ |
Verdünnung |
Keratin purified from rat enterocytes |
Lokalisation |
Cytoplasm |
Cytokeratin 17
|
Zeta Corporation |
E3 |
7 ml |
Ready-to-use |
CE/IVD |
Z2254MP |
-
|
Host |
Mouse |
Klon |
E3 |
Format |
Concentrate |
Reaktivität |
- |
Methode |
P |
Positivkontrolle |
Squamous cell carcinoma or skin. |
Verdünnung |
1:100 - 1:200 |
Isotyp |
IgG2b /κ |
Verdünnung |
Keratin purified from rat enterocytes |
Lokalisation |
Cytoplasm |
Cytokeratin 17
|
Zeta Corporation |
E3 |
0.5 ml |
Concentrate |
CE/IVD |
Z2254MS |
-
|
Host |
Mouse |
Klon |
E3 |
Format |
Concentrate |
Reaktivität |
- |
Methode |
P |
Positivkontrolle |
Squamous cell carcinoma or skin. |
Verdünnung |
1:100 - 1:200 |
Isotyp |
IgG2b /κ |
Verdünnung |
Keratin purified from rat enterocytes |
Lokalisation |
Cytoplasm |
Cytokeratin 17
|
Zeta Corporation |
E3 |
0.1 ml |
Concentrate |
CE/IVD |
Z2254MT |
-
|
Host |
Mouse |
Klon |
DC10 |
Format |
Concentrate |
Methode |
P, WB |
Vorbehandlung |
Citrate |
Positivkontrolle |
Breast Carcinoma, Skin |
Verdünnung |
1:100 |
Isotyp |
Mouse IgG1 |
Verdünnung |
Human breast cancer PMC42 cells |
Lokalisation |
Cytoplasm |
Cytokeratin 18
|
Zytomed Systems GmbH |
DC10 |
0.5 ml |
Concentrate |
RUO |
503-17012 |
-
|
Host |
Mouse |
Klon |
DC10 |
Format |
Concentrate |
Methode |
P, WB |
Vorbehandlung |
Citrate |
Positivkontrolle |
Breast Carcinoma, Skin |
Verdünnung |
1:100 |
Isotyp |
Mouse IgG1 |
Verdünnung |
Human breast cancer PMC42 cells |
Lokalisation |
Cytoplasm |
Cytokeratin 18
|
Zytomed Systems GmbH |
DC10 |
1 ml |
Concentrate |
RUO |
503-17014 |
-
|
Host |
Mouse |
Klon |
DC10 |
Format |
Concentrate |
Methode |
P |
Vorbehandlung |
Citrate |
Verdünnung |
1:50 - 1:200 |
Isotyp |
IgG1 |
Lokalisation |
Cytoplasm |
Cytokeratin 18
|
Diagnostic Biosystems |
DC10 |
1 ml |
Concentrate |
CE/IVD |
MOB187 |
-
|
Host |
Mouse |
Klon |
DC-10 |
Format |
Ready-to-use |
Methode |
F, P |
Vorbehandlung |
Citrate or Fast Enzyme |
Verdünnung |
- |
Isotyp |
Mouse IgG1 |
Lokalisation |
Cytoplasm |
Cytokeratin 18
|
Zytomed Systems GmbH |
DC-10 |
6 ml |
Ready-to-use |
RUO |
MSG016 |
-
|
Host |
Mouse |
Klon |
DC-10 |
Format |
Concentrate |
Methode |
F, P |
Vorbehandlung |
Citrate or Fast Enzyme |
Verdünnung |
1:100 - 1:200 |
Isotyp |
Mouse IgG1 |
Lokalisation |
Cytoplasm |
Cytokeratin 18
|
Zytomed Systems GmbH |
DC-10 |
1 ml |
Concentrate |
RUO |
MSK016 |
-
|